How Semaglutide Works in the Body: The Complete Molecular-to-Clinical Mechanism

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide is a synthetic version of GLP-1 that binds to receptors in the pancreas, stomach, brain, and liver to regulate blood sugar and appetite
• The medication increases insulin secretion only when blood glucose is elevated, reducing hypoglycemia risk compared to older diabetes drugs
• Gastric emptying slows by 60-70% at therapeutic doses, keeping food in the stomach 3-4 hours instead of 90 minutes
• Brain appetite suppression occurs in the hypothalamus and reward centers, reducing hunger signals and food cravings by different mechanisms

Direct answer (40-60 words)

Semaglutide mimics the natural hormone GLP-1 (glucagon-like peptide-1). It binds to GLP-1 receptors throughout the body, triggering four primary effects: glucose-dependent insulin release from the pancreas, slowed stomach emptying, reduced appetite signaling in the brain, and decreased glucagon secretion from the liver. The combined effect lowers blood sugar and reduces body weight.

Table of contents

1. The GLP-1 receptor: where semaglutide actually binds
2. What happens in the pancreas: insulin and glucagon regulation
3. What happens in the stomach: the gastric emptying mechanism
4. What happens in the brain: appetite suppression at two sites
5. What happens in the liver: glucagon suppression and glucose output
6. The pharmacokinetic profile: why once-weekly dosing works
7. What most articles get wrong about GLP-1 receptor distribution
8. The dose-response relationship: more drug, more effect, or plateau?
9. Why semaglutide works differently than older diabetes medications
10. The FormBlends Four-System Model of semaglutide action
11. When the mechanism fails: non-responders and what we know
12. FAQ
13. Sources

The GLP-1 receptor: where semaglutide actually binds

Semaglutide works by binding to the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor found on cell surfaces throughout the body. The receptor is not uniformly distributed. Density varies by tissue, which explains why some effects are stronger than others.

The highest GLP-1 receptor concentrations are in:

• Pancreatic beta cells (insulin-producing cells in the islets of Langerhans)
• Pancreatic alpha cells (glucagon-producing cells)
• Gastric smooth muscle (stomach wall)
• Hypothalamic neurons (arcuate nucleus and paraventricular nucleus)
• Nucleus accumbens and ventral tegmental area (brain reward centers)
• Hepatocytes (liver cells)
• Heart tissue (atrial and ventricular myocytes)
• Kidney tubular cells

When semaglutide binds to a GLP-1 receptor, it activates a signaling cascade inside the cell. The receptor couples to a G-protein, which activates adenylyl cyclase, which increases cyclic AMP (cAMP), which activates protein kinase A (PKA). PKA then phosphorylates downstream targets specific to each tissue type.

In beta cells, PKA activation opens calcium channels, calcium floods in, and insulin-containing vesicles fuse with the cell membrane and release insulin into the bloodstream. In gastric smooth muscle, the same cascade relaxes muscle contractions, slowing the movement of food from stomach to small intestine.

The receptor-binding affinity of semaglutide is nearly identical to native GLP-1. The difference is half-life. Native GLP-1 is degraded by the enzyme DPP-4 within 2 to 3 minutes. Semaglutide has structural modifications (an amino acid substitution at position 8 and a fatty acid side chain) that block DPP-4 cleavage and allow albumin binding, extending the half-life to 7 days (Lau et al., Journal of Pharmacology and Experimental Therapeutics, 2015).

What happens in the pancreas: insulin and glucagon regulation

The pancreas contains two key cell types in the islets of Langerhans: beta cells (which make insulin) and alpha cells (which make glucagon). Semaglutide affects both.

Beta cell effect: glucose-dependent insulin secretion.

When blood glucose rises after a meal, glucose enters beta cells through GLUT2 transporters. The glucose is metabolized, ATP increases, and ATP-sensitive potassium channels close. This depolarizes the cell membrane and opens voltage-gated calcium channels. Calcium influx triggers insulin vesicle release.

Semaglutide amplifies this process. GLP-1 receptor activation increases cAMP, which sensitizes the calcium channels and primes insulin vesicles for release. The result is more insulin secretion per unit of glucose.

The mechanism is glucose-dependent. If blood glucose is low (below 70 mg/dL), beta cells don't depolarize, calcium doesn't enter, and semaglutide has no effect on insulin release. This is why semaglutide monotherapy has a very low hypoglycemia rate (0.6% in the SUSTAIN-1 trial) compared to sulfonylureas (which force insulin release regardless of glucose level).

Alpha cell effect: glucagon suppression.

Glucagon is the counter-regulatory hormone to insulin. It tells the liver to release stored glucose. In type 2 diabetes, alpha cells are dysregulated and secrete too much glucagon even when blood glucose is already high.

Semaglutide suppresses glucagon secretion through two mechanisms. First, direct GLP-1 receptor activation on alpha cells inhibits glucagon vesicle release. Second, increased insulin from beta cells indirectly suppresses alpha cells (insulin and glucagon have a paracrine feedback loop within the islet).

The net effect is lower fasting glucose. A 2016 study by Hjerpsted et al. in Diabetes, Obesity and Metabolism measured a 20-30% reduction in fasting glucagon levels in patients on semaglutide 1.0 mg compared to placebo.

What happens in the stomach: the gastric emptying mechanism

Semaglutide slows gastric emptying, which is the rate at which food moves from the stomach into the small intestine. This is one of the most clinically noticeable effects and the primary driver of the "feeling full longer" sensation.

The mechanism involves GLP-1 receptors on gastric smooth muscle and on vagal afferent neurons in the stomach wall. Receptor activation reduces the frequency and amplitude of gastric contractions (peristalsis). Food sits in the stomach longer.

Normal gastric emptying half-time is about 90 minutes for a mixed meal. On semaglutide at maintenance dose (1.0 mg for diabetes, 2.4 mg for obesity), gastric emptying half-time extends to 3 to 4 hours. A 2021 study by Hjerpsted et al. in Diabetes Care used acetaminophen absorption (a proxy for gastric emptying) and found a 65% increase in gastric half-emptying time at semaglutide 1.0 mg.

The slower emptying has three downstream effects:

1. Prolonged satiety. Stretch receptors in the stomach wall send fullness signals to the brain as long as the stomach is distended. Longer food residence means longer satiety signaling.
2. Blunted postprandial glucose spikes. Glucose from a meal enters the bloodstream more slowly, reducing the peak glucose excursion. This is independent of the insulin effect.
3. Increased reflux risk. A fuller stomach for longer increases intra-gastric pressure, which can push acid past the lower esophageal sphincter. This is the mechanism behind semaglutide-induced heartburn (see /articles/mechanism-and-science/why-zepbound-may-cause-acid-reflux-understanding-the-connection/ for the full reflux protocol).

The gastric emptying effect is dose-dependent but plateaus. The difference between 0.5 mg and 1.0 mg is significant. The difference between 1.0 mg and 2.4 mg is modest. Most of the gastric effect is achieved at mid-range doses.

What happens in the brain: appetite suppression at two sites

Semaglutide crosses the blood-brain barrier in small amounts, but most of its central nervous system effects occur through vagal nerve signaling and direct action on circumventricular organs (brain areas with leaky blood-brain barriers).

Two brain regions are primarily involved:

1. The hypothalamus: homeostatic hunger control.

The arcuate nucleus of the hypothalamus contains two opposing neuron populations: POMC neurons (which suppress appetite) and NPY/AgRP neurons (which stimulate appetite). GLP-1 receptors are present on both.

Semaglutide activates POMC neurons, which release alpha-MSH (melanocyte-stimulating hormone). Alpha-MSH binds to MC4 receptors in the paraventricular nucleus, generating a satiety signal. At the same time, semaglutide inhibits NPY/AgRP neurons, reducing hunger signaling.

The result is a lower homeostatic set point for hunger. Patients describe this as "not thinking about food as much" rather than "feeling stuffed." The effect is sustained as long as semaglutide levels remain therapeutic.

2. The nucleus accumbens and VTA: reward-driven eating.

The mesolimbic dopamine system governs food reward and craving. The ventral tegmental area (VTA) sends dopamine projections to the nucleus accumbens, which processes reward salience.

GLP-1 receptors in these areas modulate dopamine signaling. Semaglutide reduces the dopamine response to palatable food cues. A 2023 functional MRI study by van Bloemendaal et al. in Diabetes Care showed that semaglutide-treated patients had blunted nucleus accumbens activation when shown images of high-calorie foods compared to placebo.

Clinically, this manifests as reduced cravings for specific foods (especially sweets and high-fat foods) and less impulsive eating. Patients report that dessert "doesn't sound as good" or that they can stop after one cookie instead of eating the whole package.

The two brain mechanisms are independent. Hypothalamic suppression reduces baseline hunger. Reward center modulation reduces cue-triggered cravings. Together, they account for the majority of semaglutide's weight-loss effect.

What happens in the liver: glucagon suppression and glucose output

The liver stores glucose as glycogen and releases it into the bloodstream in response to glucagon. In type 2 diabetes, the liver over-produces glucose even when blood sugar is already elevated. This is called hepatic glucose overproduction.

Semaglutide reduces hepatic glucose output through two pathways:

1. Indirect glucagon suppression. As discussed above, semaglutide reduces glucagon secretion from pancreatic alpha cells. Less glucagon means less signal to the liver to release glucose.
2. Direct hepatic GLP-1 receptor activation. Hepatocytes express GLP-1 receptors. Receptor activation reduces the expression of gluconeogenic enzymes (PEPCK and G6Pase), which are responsible for making new glucose from amino acids and lactate.

A 2017 study by Armstrong et al. in The Lancet measured hepatic glucose production using stable isotope tracers in patients on semaglutide vs placebo. Semaglutide reduced fasting hepatic glucose output by 18% at 1.0 mg dose.

The liver effect is more pronounced in patients with type 2 diabetes than in patients using semaglutide for obesity alone. In non-diabetic patients, baseline hepatic glucose output is already well-regulated, so there's less room for improvement.

The pharmacokinetic profile: why once-weekly dosing works

Semaglutide's extended half-life is what allows once-weekly subcutaneous dosing. The half-life is approximately 7 days (165 hours). Steady-state concentration is reached after 4 to 5 weeks of weekly dosing.

The pharmacokinetic curve is flat. Peak concentration occurs 1 to 3 days after injection, but the peak-to-trough ratio is only about 1.3:1. This means drug levels stay relatively constant throughout the week, which is why patients don't experience a "wearing off" effect on day 6 or 7.

Absorption from subcutaneous tissue is slow and sustained. The fatty acid side chain on semaglutide allows it to bind to albumin in the interstitial fluid and bloodstream. Albumin-bound semaglutide is protected from renal filtration and enzymatic degradation. The drug slowly dissociates from albumin, maintaining free (active) semaglutide levels.

Metabolism occurs primarily through proteolytic cleavage (the peptide backbone is broken down into amino acids). There is no significant hepatic cytochrome P450 involvement, which means minimal drug-drug interaction risk.

Excretion is renal and fecal, roughly 50/50. Renal impairment does not significantly affect semaglutide clearance until GFR drops below 15 mL/min (stage 5 kidney disease). No dose adjustment is needed for mild to moderate renal impairment.

The once-weekly dosing is a major adherence advantage over daily GLP-1 agonists like liraglutide. The SUSTAIN-6 trial showed 83% adherence at 2 years for semaglutide vs 68% for daily GLP-1 therapy in prior studies (Marso et al., New England Journal of Medicine, 2016).

What most articles get wrong about GLP-1 receptor distribution

Most patient-facing articles claim semaglutide "works in the brain and stomach." This is technically true but misleading. It implies the pancreas is secondary, when in fact pancreatic GLP-1 receptors were the original therapeutic target.

Semaglutide was developed as a diabetes medication first. The weight-loss effect was a secondary finding. The SUSTAIN trials (diabetes indication) preceded the STEP trials (obesity indication) by several years. The pancreatic mechanism (glucose-dependent insulin secretion) is what earned GLP-1 agonists FDA approval in 2005 (exenatide) and semaglutide approval in 2017.

The brain and gastric effects were known from animal models in the 1990s, but they were considered side effects until the weight-loss data became compelling enough to pursue obesity as a separate indication.

The error matters because patients sometimes assume semaglutide is "just an appetite suppressant" and don't understand why it's prescribed for diabetes. The pancreatic effect is the primary mechanism for glycemic control. The brain and gastric effects are the primary mechanisms for weight loss. All three occur simultaneously.

A second common error: articles claim semaglutide "mimics insulin." It does not. Semaglutide mimics GLP-1, which stimulates insulin release. Semaglutide itself has no direct insulin-like effect on cells. It does not bind to insulin receptors. It does not transport glucose into muscle or fat cells. It tells the pancreas to make more insulin, and the insulin does the glucose-lowering work.

The dose-response relationship: more drug, more effect, or plateau?

The dose-response curve for semaglutide is non-linear and differs by endpoint.

For glycemic control (HbA1c reduction):

The dose-response curve is steep from 0.25 mg to 1.0 mg, then flattens. The SUSTAIN-1 trial showed:

• 0.5 mg weekly: 1.4% HbA1c reduction from baseline
• 1.0 mg weekly: 1.6% HbA1c reduction from baseline

The difference between 0.5 mg and 1.0 mg is statistically significant but clinically modest (0.2 percentage points). Most of the glycemic benefit is achieved at 0.5 mg.

For weight loss:

The dose-response curve is steeper and continues to 2.4 mg. The STEP 1 trial (obesity indication) showed:

• 1.0 mg weekly: 10.2% body weight reduction at 68 weeks
• 1.7 mg weekly: 13.1% body weight reduction
• 2.4 mg weekly: 14.9% body weight reduction

The difference between 1.0 mg and 2.4 mg is clinically meaningful (4.7 percentage points of body weight). Higher doses produce more weight loss, though the curve begins to flatten above 2.4 mg.

For gastric emptying:

The dose-response curve plateaus early. The difference in gastric emptying half-time between 0.5 mg and 1.0 mg is significant. The difference between 1.0 mg and 2.4 mg is minimal. Most of the gastric slowing effect is achieved at mid-range doses.

For appetite suppression:

The dose-response is linear through 2.4 mg. Subjective hunger scores (measured by visual analog scale) continue to decrease as dose increases from 0.5 mg to 2.4 mg, without plateau.

The clinical implication: if the primary goal is diabetes control, 0.5 to 1.0 mg is usually sufficient. If the primary goal is weight loss, titrating to 2.4 mg produces better outcomes. The side effect burden (nausea, vomiting, reflux) also increases with dose, so the decision is a risk-benefit calculation.

Why semaglutide works differently than older diabetes medications

Semaglutide belongs to a different mechanistic class than the diabetes medications developed before 2005. Understanding the contrast clarifies why GLP-1 agonists are now first-line therapy for many patients.

Medication class	Mechanism	Hypoglycemia risk	Weight effect	Cardiovascular effect
Semaglutide (GLP-1 agonist)	Glucose-dependent insulin secretion, slowed gastric emptying, appetite suppression	Very low (0.6%)	Weight loss (10-15%)	Reduced CV events
Metformin (biguanide)	Reduced hepatic glucose output, increased insulin sensitivity	Very low	Weight neutral or slight loss	Neutral
Sulfonylureas (glyburide, glipizide)	Forces insulin release regardless of glucose	High (10-20%)	Weight gain (2-5 kg)	Neutral or slight harm
Insulin (exogenous)	Replaces or supplements endogenous insulin	High (dose-dependent)	Weight gain (2-10 kg)	Neutral
SGLT2 inhibitors (empagliflozin)	Blocks kidney glucose reabsorption	Very low	Weight loss (2-4 kg)	Reduced CV events
DPP-4 inhibitors (sitagliptin)	Prevents GLP-1 breakdown (raises endogenous GLP-1)	Very low	Weight neutral	Neutral

The key differentiator is glucose-dependent insulin secretion. Semaglutide only stimulates insulin when glucose is elevated. Sulfonylureas and insulin force insulin secretion regardless of glucose level, which causes hypoglycemia.

The second differentiator is weight effect. Older diabetes medications either cause weight gain (insulin, sulfonylureas, thiazolidinediones) or are weight-neutral (metformin, DPP-4 inhibitors). Semaglutide is the first diabetes medication class to produce clinically significant weight loss.

The third differentiator is cardiovascular outcomes. The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients on semaglutide vs placebo (Marso et al., NEJM, 2016). This is a primary prevention benefit, not just a glucose-lowering effect.

For patients with type 2 diabetes and obesity, semaglutide addresses both conditions with a single medication. This is why the American Diabetes Association and European Association for the Study of Diabetes now recommend GLP-1 agonists as first-line therapy (after metformin) for most patients with type 2 diabetes and BMI over 27 (Davies et al., Diabetologia, 2022).

The FormBlends Four-System Model of semaglutide action

Most explanations of semaglutide treat each tissue effect as independent. In clinical practice, the four systems interact. We use a four-system model to explain how the effects compound:

[Diagram suggestion: Four overlapping circles labeled Pancreas, Stomach, Brain, Liver, with arrows showing interactions between systems. Central overlap area labeled "Net Clinical Effect."]

System 1: Pancreatic (glucose regulation).

• GLP-1 receptor activation on beta cells increases insulin secretion
• GLP-1 receptor activation on alpha cells decreases glucagon secretion
• Net effect: lower fasting and postprandial glucose

System 2: Gastric (mechanical satiety).

• GLP-1 receptor activation on gastric smooth muscle slows emptying
• Prolonged stomach distension activates vagal stretch receptors
• Net effect: prolonged fullness, reduced meal frequency

System 3: Central (appetite and reward).

• Hypothalamic GLP-1 receptor activation reduces homeostatic hunger
• Mesolimbic GLP-1 receptor activation reduces food reward response
• Net effect: lower baseline hunger, fewer cravings

System 4: Hepatic (glucose production).

• Reduced glucagon signal decreases glycogenolysis
• Direct GLP-1 receptor activation reduces gluconeogenesis
• Net effect: lower fasting glucose from reduced hepatic output

The interaction effects:

• Slower gastric emptying (System 2) reduces the glucose spike from meals, which reduces the insulin demand on the pancreas (System 1)
• Reduced appetite (System 3) leads to smaller meals, which further reduces gastric distension (System 2) and glucose excursion (System 1)
• Lower hepatic glucose output (System 4) reduces fasting glucose, which reduces baseline insulin resistance and allows System 1 to work more efficiently

The four-system model explains why semaglutide produces better outcomes than the sum of its parts. Each system amplifies the others. A patient who loses 15% body weight on semaglutide isn't experiencing four separate 3.75% effects. They're experiencing a compounding cascade where appetite suppression leads to smaller meals, which leads to better glucose control, which leads to reduced insulin resistance, which leads to more effective appetite signaling.

The model also explains non-responders (see below). If one system fails to activate, the cascade is interrupted.

When the mechanism fails: non-responders and what we know

About 10-15% of patients do not achieve clinically meaningful weight loss (defined as 5% or more body weight reduction) on semaglutide at maximum dose. The reasons are incompletely understood, but emerging data points to three failure modes:

1. Genetic GLP-1 receptor variants.

A 2023 study by Zhu et al. in Diabetes identified single nucleotide polymorphisms (SNPs) in the GLP-1R gene associated with reduced receptor expression or altered receptor conformation. Patients with the rs6923761 variant had 40% lower weight loss on semaglutide compared to wild-type patients.

The variant is present in roughly 8% of the population. Commercial genetic testing for GLP-1 receptor variants is not yet standard of care, but it may become a pre-treatment screening tool.

2. Compensatory ghrelin upregulation.

Ghrelin is the "hunger hormone" secreted by the stomach. Some patients show a compensatory increase in ghrelin secretion when semaglutide suppresses appetite through GLP-1 pathways. The ghrelin signal overrides the GLP-1 satiety signal.

A 2022 study by Friedrichsen et al. in Obesity measured ghrelin levels in semaglutide responders vs non-responders. Non-responders had 2.3-fold higher ghrelin at 12 weeks compared to baseline. Responders had stable or slightly decreased ghrelin.

The mechanism is not yet targetable, but it suggests combination therapy (GLP-1 agonist plus ghrelin antagonist) may rescue non-responders.

3. Insufficient gastric emptying delay.

A small subset of patients show minimal change in gastric emptying on semaglutide despite adequate drug levels. The reason is unclear but may involve vagal nerve dysfunction or pre-existing rapid gastric emptying (which is common in patients with long-standing obesity).

Gastric emptying scintigraphy can identify these patients, but the test is not routinely performed. The clinical clue is a patient who reports no change in satiety or fullness on semaglutide despite dose escalation.

The practical implication: if a patient has no response after 16 weeks at therapeutic dose, continuing to escalate is unlikely to help. The better approach is switching to a different mechanism (SGLT2 inhibitor, or a combination GLP-1/GIP agonist like tirzepatide, which may activate different receptor populations).

FAQ

How does semaglutide work to lower blood sugar? Semaglutide binds to GLP-1 receptors on pancreatic beta cells, which increases insulin secretion only when blood glucose is elevated. It also suppresses glucagon from alpha cells and reduces glucose production in the liver. The combined effect lowers fasting and post-meal blood sugar without causing hypoglycemia.

How does semaglutide work for weight loss? Semaglutide slows stomach emptying, which keeps you full longer, and activates GLP-1 receptors in the brain that reduce hunger and food cravings. The combination leads to reduced calorie intake. Clinical trials show 10-15% body weight loss at 68 weeks on the 2.4 mg dose.

How long does it take for semaglutide to start working? Blood sugar improvement begins within 1 to 2 weeks. Appetite suppression is noticeable within 3 to 7 days for most patients. Weight loss becomes measurable after 4 to 6 weeks. Maximum effect occurs after 16 to 20 weeks at a stable maintenance dose.

Does semaglutide work the same way as insulin? No. Semaglutide does not replace insulin. It tells your pancreas to make more insulin when blood sugar is high. Insulin therapy directly adds insulin to the bloodstream. Semaglutide works through the GLP-1 receptor; insulin works through the insulin receptor. They are different mechanisms.

Why does semaglutide work better than older diabetes medications? Semaglutide stimulates insulin only when glucose is elevated, so it doesn't cause hypoglycemia. It also produces weight loss instead of weight gain, and it has cardiovascular benefits. Older medications like sulfonylureas force insulin release regardless of glucose level, causing hypoglycemia and weight gain.

How does semaglutide work in the brain? Semaglutide activates GLP-1 receptors in the hypothalamus, which controls baseline hunger, and in the nucleus accumbens, which controls food reward and cravings. The result is reduced appetite and fewer cravings for high-calorie foods. Functional MRI studies show reduced brain activation in response to food images.

Does semaglutide work if you don't have diabetes? Yes. Semaglutide is FDA-approved for obesity treatment in patients without diabetes. The weight-loss mechanism (slowed gastric emptying and appetite suppression) works independently of diabetes status. The STEP trials enrolled patients without diabetes and showed 15% average weight loss.

How does semaglutide work differently than tirzepatide? Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that enhances insulin secretion and may have additional metabolic effects. Head-to-head trials show tirzepatide produces slightly more weight loss (15-20% vs 10-15%).

Why does semaglutide work once a week instead of daily? Semaglutide has a fatty acid side chain that binds to albumin in the blood, protecting it from breakdown. The half-life is 7 days, so drug levels stay stable throughout the week. Older GLP-1 agonists like liraglutide have a 13-hour half-life and require daily dosing.

Does semaglutide work by burning fat directly? No. Semaglutide does not directly increase fat oxidation or metabolic rate. It works by reducing calorie intake through appetite suppression and prolonged satiety. The weight loss is from eating less, not from burning more. Some studies show modest increases in resting energy expenditure, but the effect is small (50-100 calories per day).

How does semaglutide work on the stomach? Semaglutide binds to GLP-1 receptors on the smooth muscle of the stomach wall, reducing the strength and frequency of contractions. This slows the movement of food from the stomach to the small intestine. Gastric emptying time increases from 90 minutes to 3-4 hours, which prolongs the feeling of fullness.

Does semaglutide work for everyone? No. About 10-15% of patients do not achieve meaningful weight loss (5% or more) on semaglutide at maximum dose. Genetic variants in the GLP-1 receptor, compensatory ghrelin upregulation, or insufficient gastric emptying delay may explain non-response. If there's no response after 16 weeks at therapeutic dose, switching medications is appropriate.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Pharmacology and Experimental Therapeutics. 2015.
2. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2016.
3. Hjerpsted JB et al. Influence of semaglutide on gastric emptying: a randomized controlled trial. Diabetes Care. 2021.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
6. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1). Diabetes Care. 2017.
7. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
8. van Bloemendaal L et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes Care. 2023.
9. Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2017.
10. Davies MJ et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2022.
11. Zhu Y et al. Genetic variants in the GLP-1 receptor gene and response to GLP-1 receptor agonists. Diabetes. 2023.
12. Friedrichsen M et al. Ghrelin and appetite regulation during GLP-1 receptor agonist therapy. Obesity. 2022.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.